Synonyms: Compound A [WO2022174269A1] | KT474
Compound class:
Synthetic organic
Comment: KT-474 is a PROTAC degrader of interleukin 1 receptor associated kinase 4 (IRAK4). It is in Kymera Therapeutics' pipeline and is initially being developed for potential to treat the autoimmune conditions atopic dermatitis and hidradenitis suppurativa [2]. A thalidomide analogue moiety is employed to direct the bound IRAK4 to the ubiquitin-proteasome pathway via the thalidomide-cereblon interaction.
|
|
Immunopharmacology Comments |
Degradation of the IRAK4 protein is being explored as an alternative to inhibition of its kinase activity, for clinical application in inflammatory diseases. |